ICU — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-12

• Net revenue increased $0.3 million to $0.6 million for the three months ended June 30, 2026, compared to $0.3 million net revenue for the three months ended June 30, 2025. The increase is attributable to both increased customer adoption of QUELIMMUNE and increase in existing customer demand during t…

• The following table discloses the breakdown of research and development expenses for the three months ended June 30, 2026 compared to the same period ending June 30, 2025:

• Research and development expenses for the three months ended June 30, 2026 and 2025 were $2.5 million and $1.0 million, respectively. The increase in research and development expenses of approximately $1.5 million, or 143%, was primarily driven by (i) $0.8 million increase in payroll costs primarily…

• General and administrative expenses for the three months ended June 30, 2026 and 2025 were approximately $1.8 million and $1.0 million, respectively. The increase in general and administrative was the result of (i) $0.5 million increase in Director fees primarily as a result of the Directors having …

• We recognized other income, net of approximately $0.1 million for the three months ended June 30, 2026, compared to other expense, net of approximately $0.2 million for the same period ended June 30, 2025. The change is driven by (i) a one-time $0.3 million financing charge related to our standby eq…

Text removed vs the prior filing · source: 10-Q · 2026-05-13

• (*) – there was no activity for the three months ended March 31, 2025.

• Net revenue increased $0.2 million to $0.5 million for the three months ended March 31, 2026, compared to $0.3 million net revenue for the three months ended March 31, 2025. The increase is primarily attributable to increased customer adoption of QUELIMMUNE during March 31, 2026 compared to March 31…

• The following table discloses the breakdown of research and development expense for the three months ended March 31, 2026 compared to the same period ending March 31, 2025:

• Research and development expenses for the three months ended March 31, 2026 and 2025 were $2.3 million and $2.4 million, respectively. The decrease in research and development expenses of approximately $0.1 million, or 4%, was primarily driven by (i) $0.3 million decline in clinical trial expenses, …

• General and administrative expenses for the three months ended March 31, 2026 and 2025 were approximately $1.7 million and $1.7 million, respectively, with a slight increase of $24 thousand. This was the result of (i) a $0.1 million increase in legal related fees due to litigation related expenses, …

Text removed vs the prior filing · source: 10-Q · 2026-05-13

• Our Common Stock may be delisted from Nasdaq if we do not maintain compliance with Nasdaq’s continued listing requirements. If our Common Stock is delisted, it could negatively impact us.

• Continued listing of a security on Nasdaq is conditioned upon compliance with various continued listing standards. There can be no assurance that we will be able to comply with the applicable listing standards. We have in the past received notifications of noncompliance with Nasdaq’s continued listi…

• Pursuant to Nasdaq Listing Rule 5815(d)(4)(B), we are subject to a Mandatory Panel Monitor until July 1, 2026. If, within that one-year monitoring period, the Nasdaq Listing Qualifications staff (the “Staff”) finds us again out of compliance with the Minimum Stockholders’ Equity Requirement, notwith…

• On July 31, 2025, we received a letter from Nasdaq notifying us that we were not in compliance with the $1.00 per share minimum bid price requirement for continued inclusion on Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2), (the "Minimum Bid Price Rule"). This letter had no immediate effect on t…

• On January 20, 2026, the Company received a letter from Nasdaq confirming that the Company has regained compliance with the minimum bid price requirement of the Minimum Bid Price Rule.